Home LiteratureArticle Details
PMID: 20957152 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

PLoS neglected tropical diseases ·Vol. 4 ·No. 10 ·2010-10-05

Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM

Abstract

Ebolavirus species Zaire (ZEBOV) causes highly lethal hemorrhagic fever, resulting in the death of 90% of patients within days. Most information on immune responses to ZEBOV comes from in vitro studies and animal models. The paucity of data on human immune responses to this virus is mainly due to the fact that most outbreaks occur in remote areas. Published studies in this setting, based on small numbers of samples and limited panels of immunological markers, have given somewhat different results. Here, we studied a unique collection of 56 blood samples from 42 nonsurvivors and 14 survivors, obtained during the five outbreaks that occurred between 1996 and 2003 in Gabon and Republic of Congo. Using Luminex technology, we assayed 50 cytokines in all 56 samples and performed phenotypic analyses by flow cytometry. We found that fatal outcome was associated with hypersecretion of numerous proinflammatory cytokines (IL-1β, IL-1RA, IL-6, IL-8, IL-15 and IL-16), chemokines and growth factors (MIP-1α, MIP-1β, MCP-1, M-CSF, MIF, IP-10, GRO-α and eotaxin). Interestingly, no increase of IFNα2 was detected in patients. Furthermore, nonsurvivors were also characterized by very low levels of circulating cytokines produced by T lymphocytes (IL-2, IL-3, IL-4, IL-5, IL-9, IL-13) and by a significant drop of CD3+CD4+ and CD3+CD8+ peripheral cells as well as a high increase in CD95 expression on T lymphocytes. This work, the largest study to be conducted to date in humans, showed that fatal outcome is associated with aberrant innate immune responses and with global suppression of adaptive immunity. The innate immune reaction was characterized by a "cytokine storm," with hypersecretion of numerous proinflammatory cytokines, chemokines and growth factors, and by the noteworthy absence of antiviral IFNα2. Immunosuppression was characterized by very low levels of circulating cytokines produced by T lymphocytes and by massive loss of peripheral CD4 and CD8 lymphocytes, probably through Fas/FasL-mediated apoptosis.

MeSH Terms
Adolescent Adult Apoptosis Cytokines/blood Democratic Republic of the Congo/epidemiology Disease Outbreaks Ebolavirus/immunology,pathogenicity Flow Cytometry Gabon/epidemiology Hemorrhagic Fever, Ebola/epidemiology,immunology,pathology,virology Humans Immunity, Innate Middle Aged T-Lymphocyte Subsets/chemistry,immunology Young Adult
Chemicals
Cytokines
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wauquier Nadia
Unité des Maladies Virales Émergentes, Centre International de Recherches Médicales de Franceville, Franceville, Gabon.
Becquart Pierre
Padilla Cindy
Baize Sylvain
Leroy Eric M
References (69)
69 references, click to expand
  1. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro.
    Virology. 2001 May 25;284(1):20-5 PMID: 11352664
  2. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
    Nat Med. 1999 Apr;5(4):423-6 PMID: 10202932
  3. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.
    J Comp Pathol. 2001 Nov;125(4):233-42 PMID: 11798240
  4. Human asymptomatic Ebola infection and strong inflammatory response.
    Lancet. 2000 Jun 24;355(9222):2210-5 PMID: 10881895
  5. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.
    Immunol Lett. 2002 Mar 1;80(3):169-79 PMID: 11803049
  6. Ebola hemorrhagic fever and septic shock.
    J Infect Dis. 2003 Dec 1;188(11):1613-7 PMID: 14639530
  7. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.
    J Virol. 2007 Dec;81(24):13469-77 PMID: 17928350
  8. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.
    J Immunol. 2003 Mar 15;170(6):2797-801 PMID: 12626527
  9. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells.
    J Virol. 1999 Apr;73(4):3491-6 PMID: 10074208
  10. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.
    J Virol. 2006 Jun;80(11):5168-78 PMID: 16698997
  11. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo.
    Clin Infect Dis. 2006 Jun 1;42(11):1521-6 PMID: 16652308
  12. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease.
    J Clin Invest. 1993 Apr;91(4):1301-9 PMID: 8473483
  13. Functional CD8+ T cell responses in lethal Ebola virus infection.
    J Immunol. 2008 Mar 15;180(6):4058-66 PMID: 18322215
  14. Evasion of interferon responses by Ebola and Marburg viruses.
    J Interferon Cytokine Res. 2009 Sep;29(9):511-20 PMID: 19694547
  15. Ebola haemorrhagic fever in Zaire, 1976.
    Bull World Health Organ. 1978;56(2):271-93 PMID: 307456
  16. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
    PLoS Pathog. 2008 Nov;4(11):e1000212 PMID: 19023410
  17. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues.
    J Infect Dis. 1999 Feb;179 Suppl 1:S65-75 PMID: 9988167
  18. An outbreak of Ebola in Uganda.
    Trop Med Int Health. 2002 Dec;7(12):1068-75 PMID: 12460399
  19. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure.
    Arch Pathol Lab Med. 1996 Feb;120(2):140-55 PMID: 8712894
  20. Role of natural killer cells in innate protection against lethal ebola virus infection.
    J Exp Med. 2004 Jul 19;200(2):169-79 PMID: 15249592
  21. Multiple Ebola virus transmission events and rapid decline of central African wildlife.
    Science. 2004 Jan 16;303(5656):387-90 PMID: 14726594
  22. Early immune responses accompanying human asymptomatic Ebola infections.
    Clin Exp Immunol. 2001 Jun;124(3):453-60 PMID: 11472407
  23. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.
    J Infect Dis. 1999 Feb;179 Suppl 1:S188-91 PMID: 9988183
  24. Isolation and partial characterisation of a new strain of Ebola virus.
    Lancet. 1995 May 20;345(8960):1271-4 PMID: 7746057
  25. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro.
    Virology. 2007 Jul 20;364(1):45-54 PMID: 17391724
  26. Inflammatory responses in Ebola virus-infected patients.
    Clin Exp Immunol. 2002 Apr;128(1):163-8 PMID: 11982604
  27. Structure of the Ebola VP35 interferon inhibitory domain.
    Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):411-6 PMID: 19122151
  28. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
    J Virol. 2003 Jul;77(14):7945-56 PMID: 12829834
  29. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques.
    Viral Immunol. 2004;17(3):390-400 PMID: 15357905
  30. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.
    J Virol. 2009 Apr;83(7):3069-77 PMID: 19153231
  31. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola).
    J Infect Dis. 1985 Nov;152(5):887-94 PMID: 4045253
  32. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
    J Infect Dis. 1999 Feb;179 Suppl 1:S248-58 PMID: 9988191
  33. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.
    J Virol. 2008 Mar;82(6):2699-704 PMID: 18199658
  34. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein.
    J Virol. 2008 Jun;82(11):5348-58 PMID: 18353943
  35. Evaluation in nonhuman primates of vaccines against Ebola virus.
    Emerg Infect Dis. 2002 May;8(5):503-7 PMID: 11996686
  36. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.
    Virology. 2004 Oct 25;328(2):177-84 PMID: 15464838
  37. Discovery of swine as a host for the Reston ebolavirus.
    Science. 2009 Jul 10;325(5937):204-6 PMID: 19590002
  38. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread.
    Bull World Health Organ. 1983;61(6):997-1003 PMID: 6370486
  39. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001.
    MMWR Morb Mortal Wkly Rep. 2001 Feb 9;50(5):73-7 PMID: 11686289
  40. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States.
    J Infect Dis. 1999 Feb;179 Suppl 1:S108-14 PMID: 9988173
  41. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses.
    FASEB J. 2006 Dec;20(14):2519-30 PMID: 17023517
  42. Infection and activation of monocytes by Marburg and Ebola viruses.
    J Virol. 2001 Nov;75(22):11025-33 PMID: 11602743
  43. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.
    J Virol. 2006 Jun;80(11):5156-67 PMID: 16698996
  44. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.
    Bull World Health Organ. 1978;56(2):247-70 PMID: 307455
  45. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S76-86 PMID: 9988168
  46. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.
    J Virol. 2006 Mar;80(6):3009-20 PMID: 16501110
  47. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.
    Lab Invest. 2000 Feb;80(2):171-86 PMID: 10701687
  48. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.
    Am J Pathol. 2003 Dec;163(6):2371-82 PMID: 14633609
  49. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus.
    J Comp Pathol. 2001 Nov;125(4):243-53 PMID: 11798241
  50. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses.
    FEBS Lett. 1992 Jul 6;305(3):181-4 PMID: 1299611
  51. The Ebola virus VP35 protein functions as a type I IFN antagonist.
    Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 PMID: 11027311
  52. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.
    J Virol. 2007 Jan;81(1):182-92 PMID: 17065211
  53. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.
    Am J Pathol. 2003 Dec;163(6):2347-70 PMID: 14633608
  54. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.
    PLoS One. 2010 Feb 09;5(2):e9126 PMID: 20161740
  55. Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants.
    Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17123-7 PMID: 17942693
  56. Preliminary report: isolation of Ebola virus from monkeys imported to USA.
    Lancet. 1990 Mar 3;335(8688):502-5 PMID: 1968529
  57. The Ebola virus VP35 protein is a suppressor of RNA silencing.
    PLoS Pathog. 2007 Jun;3(6):e86 PMID: 17590081
  58. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever.
    Genome Biol. 2007;8(8):R174 PMID: 17725815
  59. Lymphocyte death in a mouse model of Ebola virus infection.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S296-304 PMID: 17940964
  60. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.
    J Infect Dis. 2003 Dec 1;188(11):1630-8 PMID: 14639532
  61. Ebola virus: unravelling pathogenesis to combat a deadly disease.
    Trends Mol Med. 2006 May;12(5):206-15 PMID: 16616875
  62. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation.
    J Infect Dis. 1999 Feb;179 Suppl 1:S48-53 PMID: 9988164
  63. Pathogenesis of experimental Ebola virus infection in guinea pigs.
    J Infect Dis. 1999 Feb;179 Suppl 1:S203-17 PMID: 9988186
  64. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.
    J Infect Dis. 2003 Dec 1;188(11):1618-29 PMID: 14639531
  65. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.
    J Virol. 1996 Apr;70(4):2208-14 PMID: 8642644
  66. Ebola haemorrhagic fever: experimental infection of monkeys.
    Trans R Soc Trop Med Hyg. 1978;72(2):188-91 PMID: 418537
  67. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.
    PLoS Pathog. 2009 Jun;5(6):e1000493 PMID: 19557165
  68. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?
    Apoptosis. 2000 Feb;5(1):5-7 PMID: 11227491
  69. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.
    J Infect Dis. 1992 Oct;166(4):753-63 PMID: 1527410
Article Info
Journal
PLoS neglected tropical diseases
Abbr.
PLoS Negl Trop Dis
ISSN
1935-2735
Published
2010-10-05
Epub
2010-00-05
Language
English
Region
United States
NLM ID
101291488
PMCID
PMC2950153
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com